Mescaline for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Mescaline for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Mescaline, the long-acting psychedelic compound of peyote and San Pedro cacti, draws interest for easing depression, anxiety, and problem drinking. The strongest evidence shows only intense, mostly positive experiences in healthy volunteers; claims of lasting mental health relief, reduced alcohol misuse, and better heart health rest on surveys and uncontrolled reports. Short-term risks include nausea, day-long effects, and raised blood pressure. Benefit for health or longevity remains uncertain. (Full Review)

Protocol

Research protocol (University Hospital Basel)
300–500 mg mescaline hydrochloride
Single oral dose under supervision; 100–800 mg studied
Time of day
Morning, around 8–9 a.m.
Effects lasting 10–14 hours end before night-time sleep
Psychedelic-assisted therapy model
One to three dosing sessions
Paired with preparatory and integration psychotherapy
Time to effect
Onset and peak
About 1 hour; peak 2–4 hours
Acute effects begin and peak after dosing
Duration
10–14 hours
About 11 hours at 500 mg
Psychological changes
Days to weeks
Reported in the days to weeks after a session

Benefits

Contraindications
  • Personal or first-degree family history of schizophrenia, other psychotic disorders, or bipolar I or II disorder
  • Cardiovascular disease (coronary artery disease, myocardial infarction <6 months, stroke or transient ischemic attack <1 year, significant arrhythmia, uncontrolled hypertension ≥140/90 mmHg despite treatment)
  • Epilepsy or a history of unprovoked seizures
  • Current lithium therapy
  • Pregnancy or breastfeeding
  • Severe kidney impairment (eGFR <30 mL/min/1.73 m²)
  • History of upper gastrointestinal bleeding or esophageal varices
  • Adolescents and adults under 21
    •
Key Interactions
  • MAOIs (phenelzine, moclobemide): avoid
  • SSRIs and SNRIs (sertraline, venlafaxine): caution
  • Tricyclic antidepressants (clomipramine) and tramadol: caution
  • Antipsychotics (quetiapine, risperidone): monitor
  • Stimulants and decongestants (amphetamine, pseudoephedrine): avoid
  • Dextromethorphan: avoid
  • Supplements with serotonergic activity (St. John's wort, 5-HTP): caution
  • Blood-pressure-raising supplements (yohimbe, high-dose caffeine): avoid on session days
  • Harmala-containing plants (Syrian rue, ayahuasca vine): avoid
  • Alcohol and cannabis: caution
  • Heat exposure and strenuous exercise (sauna): avoid during effects
    •

Risk & Side Effects

  • High: Nausea and vomiting; raised blood pressure, heart rate, and body temperature; headache, fatigue, and next-day aftereffects; anxiety and challenging psychological experiences; flashbacks and persisting perceptual changes
    •
  • Low: Psychosis or mania in vulnerable people; serious poisoning and rare fatal complications; misuse and craving; long-term cognitive or mental health harm; harm during pregnancy
    •
  • Speculative: Heart valve damage with frequent repeated use
    •

Monitoring

Marker Target Why
Blood pressure <120/80 mmHg Mescaline raises pressure
Resting heart rate 50–70 beats/min Heart rate rises with dose
ECG (QTc interval) <440 ms (men), <450 ms (women) Screen for rhythm and conduction problems
eGFR >90 mL/min/1.73 m² Kidneys clear most mescaline
ALT <25 U/L Liver screening used in trials
Body temperature (during session) <37.5 °C Detects overheating
PHQ-9 score 0–4 Tracks depressive symptoms
GAD-7 score 0–4 Tracks anxiety symptoms
AUDIT score 0–7 Tracks alcohol use
Echocardiogram (repeated use only) No established target; change from own baseline Theoretical valve risk with frequent use
Pregnancy test (hCG) Negative Excludes pregnancy before dosing

Cadence: Baseline before any session; blood pressure, heart rate, and temperature every 30–60 minutes during the session; check at 24 hours; mood and anxiety scores at 1 week and 1 month; blood pressure, kidney function, and questionnaires every 6–12 months with repeated sessions

Qualitative Assessment

  • Mood stability and sense of well-being in the weeks after a session
  • Sleep quality returning to baseline within 1–2 nights
  • Anxiety levels and ability to manage stress
  • Alcohol or substance use frequency, where reduction is a goal
  • Sense of meaning, connectedness, and quality of relationships
  • Absence of persisting visual disturbances or flashbacks
  • Duration of next-day fatigue or headache
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.